Western University is advancing its leadership in biomedical research by recruiting for a Tier 1 Canada Research Chair in Mass Spectrometry Omics for Novel Therapeutics. The position represents a strategic investment in cutting-edge analytical technologies that promise to accelerate the discovery and development of new treatments for acute and chronic diseases.
Building World-Class Capacity in Analytical Omics
The Schulich School of Medicine & Dentistry, in partnership with the Faculty of Science, has posted the opportunity for a tenured appointment at the rank of Associate Professor or Professor. The successful candidate will hold a joint position in the Department of Biochemistry and the Department of Chemistry. This cross-faculty role underscores Western’s commitment to interdisciplinary collaboration between health sciences and fundamental chemistry.
Mass spectrometry omics encompasses high-throughput techniques such as proteomics, metabolomics, and lipidomics. These approaches allow researchers to profile thousands of proteins, metabolites, or lipids simultaneously, providing functional insights into cellular processes that traditional methods cannot capture at scale. The chairholder will lead efforts to apply these tools to identify molecular signatures of disease, validate therapeutic targets, and support the translation of discoveries into first-in-human trials.
Strategic Context Within Western’s Research Ecosystem
Western University has invested significantly in shared research infrastructure. The BioCORE facility in the Department of Biochemistry houses advanced mass spectrometry instrumentation for proteomics and metabolomics, along with nuclear magnetic resonance and biophysical characterization tools. The new chair is expected to assume leadership of this infrastructure, ensuring optimal utilization and mentoring junior faculty in its application.
This recruitment forms part of a broader university initiative to strengthen molecular biotherapeutics and diagnostics. Recent faculty hires across departments have added expertise in metabolomics, bioinformatics, imaging, inflammation, and public health. The chairholder will contribute to large-scale funding proposals and work closely with clinician-scientists to move discoveries from bench to bedside.
The Canada Research Chairs Program and Tier 1 Distinction
The Canada Research Chairs Program, administered by the federal government, supports outstanding researchers at Canadian universities. Tier 1 chairs are reserved for world-class leaders whose peers recognize them as international authorities in their fields. Each Tier 1 chair provides the institution with $200,000 annually for seven years, renewable once.
Nominees for Tier 1 positions must demonstrate exceptional research impact, sustained external funding, leadership in collaborative environments, and a strong record of training graduate students and postdoctoral scholars. The successful candidate at Western will first be appointed to the faculty and then submit a formal nomination for the Canada Research Chair in the next available competition.
Photo by Wonderlane on Unsplash
Equity Considerations in the Search Process
In alignment with Western’s commitment to equity, diversity, and inclusion, and to address the underrepresentation of women among chairholders, this opportunity is open only to applicants who self-identify as women. This includes individuals who self-identify as transgender, gender-fluid, non-binary, or Two-Spirit. Candidates must complete a dedicated CRC self-identification form as part of their application package.
The university continues to refine its processes to ensure accurate representation while safeguarding against misuse of self-identification declarations. Shortlisted candidates who have declared Indigenous citizenship or membership will undergo an affirmation process led by the Office of Indigenous Initiatives.
Qualifications and Expectations for Candidates
Applicants must hold a PhD or equivalent in biochemistry, chemistry, biochemical engineering, or a closely related field. They should possess a demonstrated ability to conduct independent research while fostering collaborations. A strong publication record assessed under the principles of the San Francisco Declaration on Research Assessment (DORA), evidence of national or international leadership through invited presentations, and success in securing peer-reviewed funding from agencies such as the Canadian Institutes of Health Research or the National Institutes of Health are required.
The position carries an anticipated salary range of $150,000 to $200,000, commensurate with experience, plus a comprehensive benefits package. The anticipated start date is January 1, 2027, or as negotiated. Review of applications begins July 31, 2026.
Implications for Canadian Higher Education and Research
Appointments of this caliber strengthen Canada’s position in the global biomedical research landscape. Mass spectrometry omics technologies are increasingly central to precision medicine initiatives, enabling researchers to move beyond genomics to understand dynamic molecular changes in health and disease. By attracting a Tier 1 chairholder, Western contributes to national capacity in an area with direct relevance to drug discovery, biomarker development, and personalized therapeutics.
The joint appointment model also models effective integration of medical and basic science faculties, a structure that many Canadian institutions are exploring to maximize research impact. Access to Western’s expanding core facilities, including the Western Biotherapeutics Centre and Containment Level 2 and 3 laboratories, positions the chairholder to pursue ambitious, multi-investigator projects.
Future Outlook and Opportunities for Collaboration
Once appointed, the chairholder will play a pivotal role in mentoring the next generation of researchers and expanding Western’s graduate and undergraduate training programs in analytical biochemistry and chemistry. The position is expected to catalyze new partnerships with industry, hospitals, and other academic centres focused on translating omics discoveries into clinical applications.
Western’s location in London, Ontario, offers proximity to a growing life-sciences corridor and established clinical research networks. The university’s Recruitment and Retention Office provides dedicated support for relocating faculty and their families, facilitating a smooth transition.
Photo by Erika Fletcher on Unsplash
Conclusion
Western University’s recruitment for the Tier 1 Canada Research Chair in Mass Spectrometry Omics for Novel Therapeutics signals a deliberate strategy to lead in one of the most promising frontiers of biomedical science. By combining world-class infrastructure, interdisciplinary collaboration, and a commitment to equity, the university is positioning itself—and Canada—to make meaningful advances in the development of novel therapeutics. Interested candidates are encouraged to review the full position profile and submit applications by the July 31, 2026 review date.